GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » Interest Income

Cynata Therapeutics (STU:51S) Interest Income : €0.26 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Cynata Therapeutics's interest income for the six months ended in Dec. 2023 was €0.14 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2023 was €0.26 Mil.

Cynata Therapeutics Interest Income Historical Data

The historical data trend for Cynata Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Interest Income Chart

Cynata Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.06 0.04 0.22 0.26

Cynata Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.09 0.13 0.14 0.12

Cynata Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » Interest Income
Comparable Companies
ASX:ATX ASX:NOX ASX:PTX ASX:SPL ASX:ILA ASX:ADO ASX:RAD ASX:NYR ASX:TYP ASX:BTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CYP:Australia
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Website
https://www.cynata.com
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines